Despite this variety of mechanisms of action, most mAbs are not administered as a monotherapy, but usually are combined with other modalities, particularly chemotherapy
Despite this variety of mechanisms of action, most mAbs are not administered as a monotherapy, but usually are combined with other modalities, particularly chemotherapy. the levels of phosphorylated p38 and phosphatase and tensin homolog deleted on chromosome 10 (PTEN) by all 3 HexAbs and the notable differences in the signaling events triggered by the HexAbs from those incurred by crosslinking veltuzumab or rituximab with a secondary antibody. Thus, the greatly enhanced direct toxicity of these HexAbs correlates with their ability to alter the basal expression of various intracellular proteins involved in regulating cell growth, survival, and apoptosis, with the net outcome leading to cell death. Introduction To address the clinical concerns of undesirable immmunogenicity and suboptimal pharmacokinetics, cancer therapy with monoclonal antibodies (mAbs) has evolved from murine to chimeric, humanized,…